POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; not metabolized. Dextrose is metabolized via glycolysis and oxidative phosphorylation. |
| Excretion | Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences. |
| Half-life | Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance. |
| Protein binding | Potassium is not significantly bound to plasma proteins. Less than 2% of serum potassium is protein-bound; the remainder is free and ionized. There is no specific binding protein; any minimal binding is nonspecific to albumin and globulins. |
| Volume of Distribution | Apparent volume of distribution (Vd) of potassium is large, approximately 0.5-0.6 L/kg for total body potassium, but this reflects distribution into total body water. Exchangeable potassium Vd is about 0.4 L/kg. The Vd for extracellular potassium is only about 0.05 L/kg. Clinically, Vd is not used for dosing because most potassium is intracellular; changes in serum concentration do not predict total body stores well. |
| Bioavailability | Intravenous: 100% bioavailability. Oral: Solid dosage forms have bioavailability >90% for immediate-release; enteric-coated formulations may have reduced bioavailability (70-80%) due to variability in dissolution and absorption. Liquid formulations approach 100% bioavailability. Absorption occurs throughout the small intestine via passive and active transport; bioavailability is affected by gastrointestinal motility and mucosal integrity. |
| Onset of Action | Intravenous administration: Onset of action is immediate (within seconds to minutes) as potassium is administered directly into the bloodstream, but clinical effect (e.g., ECG changes) occurs within minutes. Infusion rate and concentration influence time to effect; rapid infusion can cause immediate cardiac effects. Oral administration: Onset of action is 1-2 hours after absorption, with peak serum concentrations occurring 1-3 hours post-dose for immediate-release formulations. |
| Duration of Action | Intravenous: Duration of action is short-lived, dependent on redistribution and renal excretion. Typically, serum potassium levels return toward baseline within 4-6 hours after infusion, but sustained effects require continuous infusion or oral maintenance. Oral: Duration of action for a single dose is 4-6 hours, but controlled-release formulations can provide effect over 8-12 hours. Clinical duration must consider ongoing losses and dietary intake. |
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 mEq/hour of potassium and a maximum concentration of 40 mEq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 mEq per day for mild depletion.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: use with caution and reduce dose by 25-50%; monitor serum potassium closely. GFR <10 mL/min: avoid use unless severe hypokalemia with close monitoring; dose reduction of 50-75% recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25% and monitor potassium. Child-Pugh C: reduce dose by 50% and monitor potassium carefully due to risk of hyperkalemia from decreased hepatic clearance. |
| Pediatric use | Intravenous infusion at 0.5-1 mEq/kg/day of potassium, maximum concentration 40 mEq/L, rate not exceeding 0.5-1 mEq/kg/hour; adjust based on serum potassium and clinical response. |
| Geriatric use | Lower initial doses recommended (e.g., 10-20 mEq/day) due to age-related decline in renal function; infuse at rate ≤5 mEq/hour; monitor serum potassium and renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Potassium chloride and dextrose are normal blood constituents; breastfeeding is safe. M/P ratio not available; potassium levels in milk are regulated within normal range. |
| Teratogenic Risk | Potassium chloride and dextrose are not teratogenic. Potassium is essential for fetal development; however, hyperkalemia or hypokalemia may cause fetal arrhythmias or growth restriction. Dextrose at 5% is non-teratogenic but maternal hyperglycemia may increase risk of fetal macrosomia or neonatal hypoglycemia. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Concurrent use of potassium-sparing diuretics or ACE inhibitors without close monitoring","Conditions causing potassium retention (e.g., severe burns, Addison's disease)","Hypersensitivity to potassium chloride or dextrose"]
| Precautions | ["Risk of hyperkalemia leading to cardiac arrhythmias, especially in patients with renal impairment or receiving potassium-sparing diuretics","Extravasation can cause tissue necrosis","Monitor serum potassium, glucose, and renal function","Use with caution in patients with heart disease or conditions predisposing to hyperkalemia","High concentration infusions require central line administration"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, glucose, renal function, and ECG for arrhythmias. Assess fetal heart rate and growth if maternal electrolyte or glucose disturbances occur. |
| Fertility Effects | No direct effects on fertility. Electrolyte imbalances may impair reproductive function; correction restores normal fertility. |